Becton, Dickinson and Company (BDX) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Becton, Dickinson and Company (NYSE: BDX):

• 4/14/2026 – Becton, Dickinson and Company was given a new $175.00 price target by Royal Bank Of Canada.
• 4/10/2026 – Becton, Dickinson and Company is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $167.00 price target on the stock.
• 4/10/2026 – Becton, Dickinson and Company was upgraded by Zacks Research from “strong sell” to “hold”.
• 4/9/2026 – Becton, Dickinson and Company was upgraded by The Goldman Sachs Group, Inc. to “hold”.
• 3/23/2026 – Becton, Dickinson and Company had its price target lowered by Argus from $230.00 to $180.00. They now have a “buy” rating on the stock.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 68.52%.

Insiders Place Their Bets

In related news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 1,103 shares of company stock valued at $202,870. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.